Triple Quadrupole/Linear ion TRAP Mass Spectrometer with HPLC System

描述(由申请人提供)：本申请的目的是为购买具有多路高效液相色谱接口的混合型三重四极/线性离子陷阱(ABI 4000 QTRAP)质谱仪系统寻求资金。该仪器将扩展和升级俄亥俄州东北部地区的质谱学能力，推进克利夫兰临床基金会(CCF)及其合作机构凯斯西储大学(CWRU)、其他克利夫兰临床与转化科学奖(CTSA)成员机构和克利夫兰州立大学(CSU)的研究项目。主要用户都有NIH资助的研究资助，包括最近的多计划项目资助和SCCOR计划，所有这些项目目前都使用质谱学来询问、调查和回答与影响人类健康的重大疾病有关的关键问题。由于该地区现有仪器的充分利用，许多调查人员现在不得不提前几个月安排时间获得这项技术和/或前往遥远的(&gt；60英里)机构。如申请书中所述，支持的项目主要包括生物标记物发现和临床/翻译研究，几乎所有这些项目都利用了NCRR资助的克利夫兰CTSA。所要求的质谱计提供高吞吐量能力，确保及时访问此类仪器，同时不牺牲这些项目所需的通用性、灵敏度和专属性。这项分析活动将在我们现有的质谱学核心II内进行，该核心为CCF、CWRU、CSU和邻近机构的研究人员提供支持，进行结构解析研究、生物标记物量化、蛋白质测序/鉴定和相关服务。质谱学越来越多地被CCF和伙伴机构调查人员用作一种分析工具，需求大大超过了可获得性，导致访问严重延误，并阻碍了生产率。获得所要求的质谱计对于缓解积压的等待分析的样品至关重要。CCF已承诺投入大量资源在该地区发展质谱学，包括为质谱学核心II定制实验室空间的定制翻新，监督其运行的人员，以及确保其长期运营和维护的财务计划。公共卫生相关性：科学研究人员构成了这一共享质谱仪应用程序的主要用户群体，他们都有NIH资助的研究计划，包括参与多个非常大的基于临床样本的拨款。这些调查人员目前正在进行的项目，部分是使用现有但负担过重的质谱仪来询问、调查和回答与影响人类健康的重大疾病有关的关键问题。这些项目将极大地受益于所要求的仪器的使用，主要包括疾病生物标记物的发现和临床/转化性研究，这些研究将促进疾病状态的早期检测和/或基于临床样本结果对疾病状态或治疗计划的预后评估。

DESCRIPTION (provided by applicant): The purpose of this application is to seek funds for the purchase of a hybrid triple quadrupole/linear ion trap (ABI 4000 QTRAP) mass spectrometry system with multiplex HPLC interface. This instrument will expand and upgrade mass spectrometry capabilities within the Northeastern Ohio region, advancing research programs within the Cleveland Clinic Foundation (CCF) and its partner institution, Case Western Reserve University (CWRU), other Cleveland Clinical and Translational Science Award (CTSA) member institutions and Cleveland State University (CSU). Major Users all have NIH-funded research grants, including recent multiple Program Project Grants and SCCOR programs, all of which have projects that are currently conducted using mass spectrometry to ask, investigate and answer key questions concerning major diseases that affect human health. Due to the full utilization of available instrumentation in the region, many investigators now have to schedule time many months in advance to obtain access to this technology and/or travel to distant (>60 miles) institutions. As detailed in the application, supported projects primarily include biomarker discovery and clinical/translational studies nearly all of which also utilize the NCRR-funded Cleveland CTSA. The requested mass spectrometer provides the high through-put capabilities that will assure timely access to this type of instrumentation, while not sacrificing versatility, sensitivity and specificity required for these projects. This analytical activity will be conducted within our existing Mass Spectrometry Core II, which provides support to investigators at CCF, CWRU, CSU and neighboring institutions by performing structural elucidation studies, biomarker quantification, protein sequencing/identification, and related services. Mass spectrometry is increasingly being used as an analytical tool by CCF and partner institution investigators, with demand greatly outpacing availability, resulting in significant delays in access, and hampered productivity. The acquisition of the requested mass spectrometer is essential to alleviate the backlog of samples waiting to be analyzed. CCF has committed substantial resources to the development of mass spectrometry in the region, including custom renovation of laboratory space for Mass Spectrometry Core II, personnel to oversee its operation, and a fiscal plan to insure its operation and maintenance for the long-term. PUBLIC HEALTH RELEVANCE: The scientific investigators, who comprise the major user group for this shared mass spectrometry instrumentation application, all have NIH-funded research programs including being part of multiple, very large clinical sample-based grants. These investigators have projects that are currently conducted, in part, using the available but overburdened mass spectroscopy instrumentation to ask, investigate and answer key questions concerning major diseases that affect human health. These projects, which would benefit greatly from use of the requested instrumentation, primarily include disease biomarker discovery and clinical/translational studies that will facilitate early detection of disease states and/or provide prognostic evaluation of the disease state or treatment program based upon clinical sample outcomes.